Gibson Christopher's Form 4 filing
Recursion Pharmaceuticals, Inc. (RXRX) · filed Sep 12, 2025
- Accession no.
- 0001601830-25-000145
- Filed
- Sep 12, 2025
- Trade date
- Sep 10, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $471.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gibson ChristopherCIK 0001856369 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 10, 2025 | Class A Common Stock | CConversionAcquired | +120,000 | $0.00 | $0 | 1,074,229 | Direct | |
| Sep 10, 2025 | Class A Common Stock | SSaleDisposed | −100,000 | $4.71 | −$471,000 | 974,229 | Direct | |
| Sep 10, 2025 | Class A Common Stock | GGiftDisposed | −20,000 | $0.00 | $0 | 954,229 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 10, 2025 | Class A Common Stock | CConversionDisposed | −120,000 | $0.00 | $0 | 5,253,034 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.